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In a recent issue ofChemistry & Biology, Tropak et al. [1] reported a high-throughput screening assay
to identify b-hexosaminidase inhibitors that act as pharmacological chaperones and are potential
drug candidates for the treatment of Tay-Sachs disease.Genetic conformational diseases are
often caused by modest mutations in
proteins that lead to unnecessary
recognition of the mutant protein by
the endoplasmic reticulum (ER) quality
control systemasmisfolded. These mu-
tations classically occur outside of the
predicted functional domain of the af-
fected proteins such that interventions
to allow their release from the quality
control system and their targeting to
their proper site of action could restore
function [2]. Classic examples of such
diseases include cystic fibrosis, neph-
rogenic diabetes insipidus, hypogona-
dotropic hypogonadism, and various
lysosomal storage disorders such as
GM2 gangliosidosis, Fabry, Gaucher,
and Morquio B diseases.
Pharmacological chaperones are
small molecules that can bind and sta-
bilize the folding intermediates of the
mutant proteins thus favoring their
proper folding, ER export, and subse-
quent trafficking to their normal sub-
cellular location [3]. In most instances,
pharmacological chaperones that can
rescue folding, trafficking, and func-
tion of mutant proteins have been
found among ligands that were already
known to bind to the affected proteins
thus conferring a measure of selectiv-
ity. For example, specific receptor
antagonists in the case of diseasesresulting from mutations in G protein-
coupled receptors (like V2-vaso-
pressin and gonadotropin-releasing
hormone receptors for nephrogenic
diabetes insipidus and hypogonado-
tropic hypogonadism, respectively
[4,5]) and competitive enzyme inhibi-
tors for lysosomal storage disorders
[6] were found to increase the levels
of active receptors and enzymes in
cellular systems, indicating that such
compounds could have therapeutic
value. Consistent with this notion,
a small scale clinical trial carried out
in nephrogenic diabetes insipidus
patients confirmed the therapeutic
activity of a pharmacological chaper-
one, as administration of a vasopressin
antagonist significantly improved kid-
ney functions in five patients harboring
three distinct mutations [7].
The use of an antagonist or inhibitor
to treat a disease resulting from a loss
of function mutation may appear con-
tradictory, but is based on the idea
that the high affinity binding of these
compounds to the mutant protein
provides sufficient interaction time to
promote proper folding and escape
from the ER quality control system.
Obviously, the inhibitors then need to
dissociate from the rescued enzyme/
receptor to permit their activity. It fol-
lows that detailed pharmacokineticChemistry & Biology 14, March 2007 ªstudies are needed to find a drug ad-
ministration regimen that would result
in the optimum therapeutic activity
of individual pharmacological chaper-
ones.
Based on the idea that inhibitors can
act as pharmacological chaperones
and rescue the activity of protein func-
tion, Tropak et al. [1] developed a real
time, high-throughput assay to identify
new inhibitors of human b-hexosami-
dase that could have pharmacolog-
ical activity in the treatment of two
forms of GM2 gangliosidosis, infantile
Tay-Sachs disease (ISD) and adult
Tay-Sachs disease (ATSD). These
diseases result from mutations in
the gene encoding b-hexosaminidase
that render the enzyme unstable
most likely due to misfolding, thus
making them potential targets for the
therapeutic action of pharmacological
chaperones. The fluorescence-based
in vitro assay developed by the authors
uses purified enzyme and identified 24
confirmed inhibitors of the enzymatic
activity out of a commercially available
50,000 compound library. Three of
these compounds, belonging to dis-
tinct classes of chemical structures,
were then selected to study their
potential action as pharmacological
chaperones in treatment of Tay-Sachs
disease.2007 Elsevier Ltd All rights reserved 241
Chemistry & Biology
PreviewsIn a cell culture system, the three
compounds were found to increase
the amount and activity of b-hexosa-
minidase in fibroblasts obtained from
patients with ISD and ATSD. Analysis
of the mode of action of the inhibitors
revealed that they most likely function
by stabilizing the enzyme, and thus
qualify to be called pharmacological
chaperones. Interestingly, the ob-
served increase in activity (3-fold in
the best case) would be predicted to
confer sufficient function to have
beneficial effects in patients, making
them good candidates for the devel-
opment of clinically useful drugs. The
three novel pharmacological chaper-
ones displayed better selectivity pro-
files than the known b-hexosamini-
dase inhibitor that was previously
shown to have pharmacological chap-
erone activity [8], leading to the hope
that they could have fewer undesirable
off-target effects. Also of significant
interest, some of the identified com-
pounds share chemical scaffolds with
drugs that have already been ap-
proved by the FDA, increasing the like-
lihood that they could meet the criteria
for good drug candidates.
In addition to identifying novel phar-
macological chaperones with thera-Reprogramming
Salam A. Shaaban1,* and Mark T. Be
1 OSI Pharmaceuticals Inc., 1 Bioscience P




current study by Kubicek et al. [1]
opening the way to new epigene
An important part of the pathogenesis
of cancer lies in the inactivation of
tumor suppressor genes, which can
be achieved either genetically or epi-
genetically. Epigenetic alterations re-
fer to changes in gene expression
that do not result from alterations in
242 Chemistry & Biology 14, March 2007peutic potential for the treatment of
Tay-Sach diseases, the present study
represents a proof of principle that
high-throughput assays can be used
to identify new chemical entities with
pharmacological chaperone activity—
a path that will undoubtedly be fol-
lowed by investigators in search of
novel therapeutic avenues for treating
conformational diseases. Although
the present screening campaign was
searching for inhibitors, there are no
a priori theoretical reasons why other
types of ligands (agonists, allosteric
regulators, etc.) that bind and stabilize
misfolded proteins could not also
act as pharmacological chaperones.
Thus, high-throughput screens based
on the ability of compounds to restore
normal subcellular targeting, indepen-
dent of their intrinsic signaling activi-
ties, are also likely to be carried out in
the near future.
Upcoming and ongoing clinical trials
for Tay-Sachs disease and other lyso-
somal storage disorders such as Fabry
disease will soon tell us if the initial
clinical results for pharmacological
chaperones [7] can be generalized. It
will be interesting to see if screening
for novel pharmacological chaperones
will become a common approach inthe Histone Code
dford2,*
ark Drive, Farmingdale, NY 11735, USA
ncer Center, Science Park-Research Division
.A.S.), mtbedford@mdanderson.org (M.T.B.)
s, like G9a, play central roles in the
reports the identification of a G9a s
tic cancer therapies.
the DNA sequence. Epigenetic mecha-
nisms include DNA methylation, and
histone protein acetylation and meth-
ylation. Both DNA methylation and
histone acetylation have been the tar-
get of small-molecule therapies [2, 3],
while the development of compounds
ª2007 Elsevier Ltd All rights reservedthe search for conformational disease
treatments.
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regulation of gene expression. A
mall-molecule inhibitor, thereby
that target lysine and arginine methyl-
transferases has lagged behind. In a re-
cent issue of Molecular Cell, Kubicek
et al. [1] described screening for and
identification of a highly specific, small
molecular weight histone lysine meth-
yltransferase (HKMT) inhibitor that
